EUVIMEDEUVIMED entdecken
Kohortenstudie

COVID ‐19 Vaccination Effectiveness and Clinical Outcomes in Chronic Liver Disease: A Nationwide Retrospective Cohort Study

Jae Yoon Jeong, Bomi Kim, Danbee Kang iD, Eun-Jeong Joo, Ju-Yeon Cho, Jung Hee Kim iD, Soo Jin Park, Hyunwoo Oh iD, Yong Kyun Cho, Byung Ik Kim, Won Sohn iD

Liver International · 2026-07 · 46 (7)

DOI: 10.1111/liv.70724 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver International, online erschienen am 03.06.2026. Verfasst von Jae Yoon Jeong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, S…. Hauptthemen laut MEDLINE: Liver Cirrhosis, COVID-19, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Korean Association for the Study of the Liver.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims This study investigated the effectiveness of COVID‐19 vaccination in decompensated cirrhosis.

Methods

This study comprised a population‐based cohort of 1 583 777 patients with chronic liver disease (CLD), including decompensated cirrhosis, from the National Health Insurance Service data in South Korea. The primary outcome was the risk of COVID‐19 within 6 months after vaccination between 26 February 2021 and 31 December 2021. Hospitalisation and all‐cause mortality rates were also investigated. Target trial specifications with propensity score matching were used to minimise the bias between the unvaccinated and vaccinated groups.

Results

The mean age of patients was 54.2 years, and 54.5% were men. In total, 61 765 patients (3.9%) had decompensated cirrhosis. Compared to the unvaccinated group, the vaccinated group exhibited a lower risk of COVID‐19 (hazard ratio [HR] = 0.94; 95% confidence interval [CI] = 0.91–0.97), hospitalisation (HR = 0.86; 95% CI = 0.83–0.89), and all‐cause mortality (HR = 0.27; 95% CI = 0.20–0.36) in CLD. However, there was no statistical difference in the clinical outcomes among patients with decompensated cirrhosis with respect to COVID‐19 vaccination. The multivariable analysis determined that COVID‐19 vaccination reduced all‐cause mortality in CLD (HR = 0.39; 95% CI = 0.32–0.49) and decompensated cirrhosis increased all‐cause mortality in patients with COVID‐19 (HR = 2.94; 95% CI = 2.15–4.02). These results were consistent during the pre‐Delta and Delta‐variant periods.

Conclusions

COVID‐19 vaccination reduced the risk of COVID‐19, hospitalisation, and mortality in CLD. However, patients with decompensated cirrhosis had a poor prognosis independently of COVID‐19 vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisCOVID-19COVID-19 VaccinesVaccine EfficacyHumansMaleMiddle AgedFemaleRepublic of KoreaRetrospective StudiesHospitalizationAgedSARS-CoV-2AdultChronic DiseaseVaccinationLiver Diseases

Stichwörter der Autor:innen

COVID‐19hospitalisationliver cirrhosisliver diseasesprognosisvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
  • Division of Infectious Diseases, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
  • Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York, USA.
  • Division of Gastroenterology, Department of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Dongtan, Republic of Korea.

ORCID-Profile: Danbee Kang, Jung Hee Kim, Hyunwoo Oh, Won Sohn

Förderung

  • Korean Association for the Study of the Liver

Zitieren

APA

Jeong, J. Y., Kim, B., Kang, D., Joo, E. J., Cho, J. Y., Kim, J. H., Park, S. J., Oh, H., Cho, Y. K., Kim, B. I., & Sohn, W. (2026). COVID ‐19 Vaccination Effectiveness and Clinical Outcomes in Chronic Liver Disease: A Nationwide Retrospective Cohort Study. Liver International, 46(7). https://doi.org/10.1111/liv.70724

Vancouver

Jeong JY, Kim B, Kang D, Joo EJ, Cho JY, Kim JH, et al. COVID ‐19 Vaccination Effectiveness and Clinical Outcomes in Chronic Liver Disease: A Nationwide Retrospective Cohort Study. Liver International. 2026;46(7). doi:10.1111/liv.70724

BibTeX
@article{Jeong2026,
  author = {Jeong, Jae Yoon and Kim, Bomi and Kang, Danbee and Joo, Eun-Jeong and Cho, Ju-Yeon and Kim, Jung Hee and Park, Soo Jin and Oh, Hyunwoo and Cho, Yong Kyun and Kim, Byung Ik and Sohn, Won},
  title = {COVID ‐19 Vaccination Effectiveness and Clinical Outcomes in Chronic Liver Disease: A Nationwide Retrospective Cohort Study},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1111/liv.70724}
}
Kostenlos starten →